ANIK icon

Anika Therapeutics

15.03 USD
+0.00
0.00%
At close Apr 1, 4:00 PM EDT
After hours
15.03
+0.00
0.00%
1 day
0.00%
5 days
-2.40%
1 month
-12.62%
3 months
-7.28%
6 months
-38.07%
Year to date
-7.28%
1 year
-41.52%
5 years
-47.21%
10 years
-63.39%
 

About: Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.

Employees: 288

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

48% more call options, than puts

Call options by funds: $46K | Put options by funds: $31K

0% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 39

2.95% less ownership

Funds ownership: 88.58% [Q3] → 85.62% (-2.95%) [Q4]

11% less funds holding

Funds holding: 122 [Q3] → 109 (-13) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]

36% less capital invested

Capital invested by funds: $324M [Q3] → $206M (-$118M) [Q4]

44% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 27

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$20
33%
upside
Avg. target
$20
33%
upside
High target
$20
33%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Barrington Research
Michael Petusky
35% 1-year accuracy
25 / 72 met price target
33%upside
$20
Outperform
Maintained
13 Mar 2025

Financial journalist opinion

Based on 3 articles about ANIK published over the past 30 days

Neutral
Seeking Alpha
2 weeks ago
Anika Therapeutics, Inc. (ANIK) Q4 2024 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Matt Hall - Director, Corporate Development & Investor Relations Cheryl Blanchard - President & Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Jim Sidoti - Sidoti & Co. Mike Petusky - Barrington Research Operator Good morning, ladies and gentlemen, and welcome to Anika's Fourth Quarter and Year End Earnings Conference Call. At this time, all lines are in listen-only mode.
Anika Therapeutics, Inc. (ANIK) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
2 weeks ago
Anika Reports Fourth Quarter and Full Year 2024 Financial Results
Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Strategic Sale of Parcus Medical complete; resources refocused on programs positioned to generate significantly higher returns BEDFORD, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the Osteoarthritis ("OA") Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 31, 2024.
Anika Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
GlobeNewsWire
3 weeks ago
Anika Completes Divestiture of Parcus Medical
Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio
Anika Completes Divestiture of Parcus Medical
Neutral
GlobeNewsWire
1 month ago
Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025
BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2024 financial results after the close of the market on Wednesday, March 12, 2025 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025
Neutral
GlobeNewsWire
1 month ago
Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference
BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego on Monday, March 10, 2025 at 2:30pm PT / 5:30pm ET. Management will also participate in one-on-one investor meetings throughout the event.
Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference
Neutral
GlobeNewsWire
3 months ago
Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference
BEDFORD, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET. Management will also participate in one-on-one investor meetings throughout the event.
Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference
Neutral
GlobeNewsWire
4 months ago
Anika To Participate in December 2024 Investor Conferences
BEDFORD, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that senior management will participate in the following upcoming conferences.
Anika To Participate in December 2024 Investor Conferences
Negative
Zacks Investment Research
4 months ago
New Strong Sell Stocks for November 11th
AMRK, ANIK and ALG have been added to the Zacks Rank #5 (Strong Sell) List on November 11, 2024.
New Strong Sell Stocks for November 11th
Neutral
Seeking Alpha
4 months ago
Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development and IR Cheryl Blanchard - President and CEO Steve Griffin - EVP, CFO and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Co. Mike Petusky - Barrington Research Operator Good morning, ladies and gentlemen, and welcome to Anika's Third Quarter Earnings Conference Call. [Operator Instructions].
Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript
Neutral
PRNewsWire
5 months ago
Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics
WEST BRIDGEWATER, Mass. , Oct. 31, 2024 /PRNewswire/ -- Executive management from Primo Medical Group along with others, combined to acquire Arthrosurface, Inc., a leading provider of joint restoration and preservation solutions for active patients, from Anika Therapeutics (NASDAQ: ANIK).
Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics
Charts implemented using Lightweight Charts™